{
    "organizations": [],
    "uuid": "e00cb6848758ad3c0615dd1c0218b15376ae1a3a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-reata-provides-update-on-phase-2-p/brief-reata-provides-update-on-phase-2-portion-of-cardinal-study-of-bardoxolone-methyl-in-patients-with-alport-syndrome-idUSASC09VLI",
    "ord_in_thread": 0,
    "title": "BRIEF-Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 11 (Reuters) - Reata Pharmaceuticals Inc:\n* REATA PROVIDES UPDATE ON THE PHASE 2 PORTION OF THE CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME\n* IN STUDY, BARDOXOLONE TREATMENT PRODUCED “SIGNIFICANT” INCREASE IN KIDNEY FUNCTION MAINTAINED THROUGH WEEK 36\n* BARDOXOLONE CONTINUES TO BE WELL-TOLERATED IN ALPORT SYNDROME PATIENTS\n* ADVERSE EVENTS HAVE BEEN GENERALLY MILD TO MODERATE IN SEVERITY, NO DRUG-RELATED SERIOUS ADVERSE EVENTS BEEN REPORTED IN TRIAL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-12T04:59:00.000+03:00",
    "crawled": "2018-04-12T13:53:20.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "reata",
        "pharmaceutical",
        "inc",
        "reata",
        "provides",
        "update",
        "phase",
        "portion",
        "cardinal",
        "study",
        "bardoxolone",
        "methyl",
        "patient",
        "alport",
        "syndrome",
        "study",
        "bardoxolone",
        "treatment",
        "produced",
        "significant",
        "increase",
        "kidney",
        "function",
        "maintained",
        "week",
        "bardoxolone",
        "continues",
        "alport",
        "syndrome",
        "patient",
        "adverse",
        "event",
        "generally",
        "mild",
        "moderate",
        "severity",
        "serious",
        "adverse",
        "event",
        "reported",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}